In most cancer subtypes JAK-STAT pathway inhibition serves as a potential chemotherapeutic treatment, but selective targeting remains a challenge due to variabilities in patient genetics, epigenetics, and variations in tumor subtypes. Here, SOAT1 is linked to neoplasm.